The U.S. Food and Drug Administration issued a new draft guidance to industry for developing plans to enroll more participants from underrepresented racial and ethnic populations in the U.S. into clinical trials – expanding on the agency’s previous guidances for industry to improve clinical trial diversity.
Remember back in March and April and May of 2020, when people prefaced their plans for the future with, “When we get back to normal”? We never did, and we never will. The COVID experience has forever changed how all of us view the world, how we interact with each other … and, of course, how we interact with healthcare brands and what we expect from them. In seeking out insights from pharma’s wise heads for Med Ad News’ annual Agenda report, we tried to maneuver around COVID at least a little, to see what else was going on in the industry. But the plain fact is that we couldn’t, not really.
Investor interest in the development of prescription digital therapeutics (PDTs) grew enormously in 2021, spurred by the telehealth boom of the pandemic. But determining approval pathways with regulators as well as methods to prove the value of prescription digital therapeutics (PDTs) will be essential in making sure that payers accept these very new treatments, according to Med Ad News’ annual special feature, “Value of Medicines.”
As healthcare companies continue to refine and expand methods of achieving diversity, equity and inclusion, DE&I leaders know their efforts are not a sprint, but part of an ongoing journey.
For the fourteenth year, Med Ad News chose new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.
Telehealth boomed during the pandemic, and experts believe that even with the world opening back up, pharma companies will have to continue to shift and strengthen tactics to reach physicians and patients virtually.
Greater Than One Chief Technology Officer Ken Winell explores and offers considerations to how innovation and changes in telemedicine can fit comfortably, and successfully, into the U.S. healthcare ecosystem.
The impact of the global pandemic has been felt across all facets of life, including medical care. Telehealth, which was already gaining in popularity, received a major boost as a result of COVID: Before the pandemic, 56 percent of Americans did not believe they could receive the same level of care from telehealth compared to in-person care, but recent polling shows nearly 80 percent of Americans now say it is possible.
Although the endocannabinoid system has been intensely studied, there are still few drugs approved or in development that interact with it.
Yuval Cohen, Ph.D., CEO of Corbus Pharmaceuticals Holdings, spoke with Med Ad News about what the endocannabinoid system is, Corbus’ pipeline of drugs, and why he thinks there will be a flood of drugs targeting the endocannabinoid system.